India markets closed

Abeona Therapeutics Inc. (ABEO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.86000.0000 (0.00%)
At close: 4:00PM EDT

2.8600 0.00 (0.00%)
After hours: 4:16PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close2.8600
Open2.8400
Bid2.8200 x 4000
Ask2.8600 x 2200
Day's range2.8000 - 2.9250
52-week range1.3500 - 5.1900
Volume570,920
Avg. volume988,023
Market cap239.376M
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)-1.7210
Earnings date06-May-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.43
  • Abeona Restarts Enrollment in Connective Tissue Disorder Study
    Zacks

    Abeona Restarts Enrollment in Connective Tissue Disorder Study

    Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.

  • GlobeNewswire

    Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies

    Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivotal Phase 3 VIITAL™ study of EB-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Enrollment in the VIITAL™ study at Stanford University Medical Center was paused in March 2020 in order to redirect healthcare resources to COVID-19 patients and to ensure the safety of study participants and site staff.

  • GlobeNewswire

    Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting

    Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the upcoming Society for Pediatric Dermatology (SPD) 45th Annual Meeting, to be held virtually during July 10-12, 2020. RDEB is a rare connective tissue disorder without an approved treatment, in which patients suffer from severe epidermal wounds that severely impact their lives. The first abstract features a more detailed examination than previously disclosed of data on long-term pain relief following durable healing of wounds in RDEB patients treated with EB-101 in a Phase 1/2 study.